Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
about
Profile of veliparib and its potential in the treatment of solid tumorsThe Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaEfficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaEvaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.Current trends in mouse models of glioblastoma.Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.PARP inhibitors: the journey from research hypothesis to clinical approval.ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
P2860
Q26801272-45CF7C2B-C91F-4E7C-BAFA-CBA6E658510CQ35463482-59EB114D-894D-4B13-B00E-F65848AC195BQ35799917-F0D9FFFA-C4DE-40BC-B50B-05EDDB841A48Q36887663-32F29BE6-2958-409D-B139-7D7A529BA117Q37217995-05E4EF9A-E3D0-4712-9FCE-C98B8375C744Q37708325-90740C56-708E-47D0-9C1C-AAFA6EF4F924Q38597700-820ABFF7-D6EC-41DE-810B-54CA43AAA66EQ42083096-2BB4B038-514F-4D93-969A-172C4AF4FE69Q45973213-17C75A71-4A7A-43F5-9D22-6B6FB53FACB7Q47169542-C6A9CDF7-9D2C-4D5A-8307-C610122E2C00Q47894479-11F8862B-9D0A-4593-911E-697C22CC4351Q53682668-80C92114-0420-486D-BA91-C327AD4A76BAQ58699862-ACE74A34-4BF1-4874-83DE-DF1E9131BAEC
P2860
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@ast
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@en
type
label
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@ast
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@en
prefLabel
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@ast
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@en
P2093
P2860
P1476
Discordant in vitro and in viv ...... lastoma multiforme xenografts.
@en
P2093
Ann C Mladek
Brett L Carlson
Felix Boakye-Agyeman
Jann N Sarkaria
Katrina K Bakken
Mark A Schroeder
Sani H Kizilbash
Shiv K Gupta
P2860
P304
P356
10.1158/1078-0432.CCR-13-3446
P407
P577
2014-05-16T00:00:00Z